 Tiziana Life Sciences Ltd NASDAQ:TLSA has announced that it plans to submit an Investigational New Drug Application IND for a phase 1 trial of intranasal foralumab in Alzheimers disease patients. The news comes after the clinical-stage biopharmaceutical company received an affirmative written response from the US Food and Drug Administration FDA on a Pre-Investigational New Drug Application PIND. 